Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  European Journal of Endocrinology

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/EJE.0.1420466PMID 10802523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.

  1998cited by this paper
• GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited.

  1998cited by this paper
• Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings.

  1998cited by this paper
• Cognitive and Noncognitive Symptoms in Dementia Patients: Relationship to Cortisol and Dehydroepiandrosterone

  1998influential reference
• Immunohistochemical study of GABA(A) receptor beta2/3 subunits in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes.

  1997cited by this paper
• Cortisol secretion and Alzheimer's disease progression.

  1997cited by this paper
• Corticotropin‐Releasing Factor (CRF), CRF‐Binding Protein (CRF‐BP), and CRF/CRF‐BP Complex in Alzheimer's Disease and Control Postmortem Human Brain

  1997cited by this paper
• Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation.

  1997cited by this paper
• Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease.

  1996influential reference
• Enhanced adrenal sensitivity to adrenocorticotrophic hormone (ACTH) is evidence of HPA axis hyperactivity in Alzheimer's disease

  1996cited by this paper
• A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer

  1996cited by this paper
• Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists?

  1995cited by this paper
• From stress to cognition

  1995cited by this paper
• Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease.

  1995cited by this paper
• Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia.

  1995cited by this paper
• Corticotropin-releasing factor. From stress to cognition.

  1995cited by this paper
• GABAergic Deafferentation Hypothesis of Brain Aging and Alzheimer's Disease; Pharmacologic Profile of the Benzodiazepine Antagonist, Flumazenil

  1995cited by this paper
• Regulation of the Hypothalamic‐Pituitary‐Adrenal Axis in Dementia Disorders

  1994cited by this paper
• The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus.

  1994cited by this paper
• Hypothalamic dysfunction in dementia.

  1994cited by this paper
• Neurosteroids and aggressive behaviour in Alzheimer's disease.

  1994cited by this paper
• Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects.

  1994cited by this paper
• Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.

  1994cited by this paper
• Neuroendocrine studies in dementia patients: responses of plasma GH and PRL following bromocriptine administration

  1994cited by this paper
• Relationship between mental impairment and HPA axis activity in dementia disorders.

  1994cited by this paper
• Cerebrospinal fluid neuropeptides in mood disorder and dementia.

  1992cited by this paper
• Neurosteroids: Endogenous bimodal modulators of the GABAA receptor mechanism of action and physiological significance

  1992cited by this paper
• Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance.

  1992cited by this paper
• Antiglucocorticoid effects of DHEA-S in Alzheimer's disease.

  1992cited by this paper
• Twenty-four-hour beta-endorphin secretory pattern in Alzheimer's disease.

  1992cited by this paper
• Different regulation of adrenocorticotropin and cortisol secretion in young, mentally healthy elderly and patients with senile dementia of Alzheimer's type.

  1991cited by this paper
• Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia.

  1991cited by this paper
• Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain.

  1991cited by this paper
• Cerebrospinal fluid corticotropin‐releasing factor levels and stimulation test in dementia of the alzheimer type

  1990cited by this paper
• Dementia of the Alzheimer type and hypothalamus‐pituitary‐adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels

  1990cited by this paper
• DEHYDROEPIANDROSTERONE (DHEA) AND ITS SULFATE (DHEAS) AS NEURAL FACILITATORS: EFFECTS ON BRAIN TISSUE IN CULTURE AND ON MEMORY IN YOUNG AND OLD MICE. A CYCLIC GMP HYPOTHESIS OF ACTION OF DHEA AND DHEAS IN NERVOUS SYSTEM AND OTHER TISSUES

  1990cited by this paper
• Antiglucocorticoid actions of dehydroepiandrosterone and low concentrations in Alzheimer's disease.

  1989cited by this paper
• Cerebrospinal fluid concentrations of corticotropin‐releasing hormone (CRH) and corticotropin (ACTH) are reduced in patients with Alzheimer's disease

  1987cited by this paper
• The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis.

  1986cited by this paper
• Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease

  1986cited by this paper
• Dexamethasone Suppression Test and Serum Prolactin in Dementia Disorders

  1983cited by this paper
• Corticotropin-releasing factor.

  1982cited by this paper

• Neurosteroids and Translocator Protein (TSPO) in neuroinflammation.

  2024cites this paper
• Decreased serum allopregnanolone and progesterone levels in male patients with bipolar disorder and their effects on cognitive functions

  2023cites this paper
• The Role of Steroidomics in the Diagnosis of Alzheimer’s Disease and Type 2 Diabetes Mellitus

  2023cites this paper
• Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses

  2022cites this paper
• CIA_A_297483 451..463

  2021cites this paper
• Gene Set Index Based on Different Modules May Help Differentiate the Mechanisms of Alzheimer’s Disease and Vascular Dementia

  2021cites this paper
• Intact circadian rhythm despite cortisol hypersecretion in Alzheimer's disease: A meta-analysis.

  2021cites this paper
• Biosynthesis and signalling functions of central and peripheral nervous system neurosteroids in health and disease

  2020cites this paper
• Inhibition of 5 α reductase impairs cognitive performance, alters dendritic morphology and increases tau phosphorylation in the hippocampus of male 3xTg-AD mice.

  2020cites this paper
• GABA-A receptor modulating steroids in acute and chronic stress; relevance for cognition and dementia?

  2019cites this paper
• Central intracrine DHEA synthesis in ageing-related neuroinflammation and neurodegeneration: therapeutic potential?

  2018cites this paper
• Neurosteroid Metabolites of Gonadal Steroid Hormones in Neuroprotection: Implications for Sex Differences in Neurodegenerative Disease

  2018cites this paper
• Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine‐induced deficits in cognitive function and social interaction

  2018cites this paper
• ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease.

  2018cites this paper
• Targeting psychologic stress signaling pathways in Alzheimer’s disease

  2017influential citation
• 4.16 – Aging and Alzheimer's Disease

  2017cites this paper
• EVALUATION OF THERAPEUTIC POTENTIAL OF CLEOME VISCOSA ON CORTICOSTERONE INDUCED EXPERIMENTAL DEMENTIA IN MICE

  2016cites this paper
• Effects of dehydroepiandrosterone on cognition : an electrophysiological approach

  2016cites this paper
• Steroid Profiling in Male Wobbler Mouse, a Model of Amyotrophic Lateral Sclerosis.

  2016cites this paper
• Preliminary evidence of altered steroidogenesis in women with Alzheimer's disease: Have the patients "OLDER" adrenal zona reticularis?

  2016cites this paper
• Reduced sulfotransferase SULT2A1 activity in patients with Alzheimer's disease.

  2015cites this paper
• Analytical challenges for measuring steroid responses to stress, neurodegeneration and injury in the central nervous system.

  2015cites this paper
• Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

  2015cites this paper
• DHEA and cognitive function in the elderly.

  2015cites this paper
• Reduced Sulfotransferase SULT 2 A 1 Activity in Patients With Alzheimer ́ s Disease

  2015cites this paper
• Allopregnanolone attenuates Aβ25-35-induced neurotoxicity in PC12 cells by reducing oxidative stress.

  2015cites this paper
• Frontiers in therapeutic development of allopregnanolone for Alzheimer’s disease and other neurological disorders

  2014cites this paper
• Brief but chronic increase in allopregnanolone cause accelerated AD pathology differently in two mouse models.

  2013cites this paper
• Advances in neurosteroids: role in clinical practice

  2013cites this paper
• Stress steroids as accelerators of Alzheimer's disease. : Effects of chronically elevated levels of allopregnanolone in transgenic AD models.

  2013influential citation
• Effects of dehydroepiandrosterone supplementation during stressful military training: A randomized, controlled, double-blind field study

  2012cites this paper
• Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice

  2012cites this paper
• Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.

  2012cites this paper
• Neurosteroids and GABAA Receptor Interactions: A Focus on Stress

  2011cites this paper
• The Role of DHEA in Mental Disorders

  2011cites this paper
• Neurosteroids in clinical practice: implications for women’s health

  2011cites this paper
• Endogenous progesterone is associated to amyotrophic lateral sclerosis prognostic factors

  2011cites this paper
• Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.

  2011cites this paper
• Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

  2010cites this paper
• Progesterone enhances learning and memory of aged wildtype and progestin receptor knockout mice.

  2010cites this paper
• Aging and Alzheimer's Disease

  2009cites this paper
• Progesterone reduces depression-like behavior in a murine model of Alzheimer’s Disease

  2009cites this paper
• Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

  2009cites this paper
• Allopregnanolone and Pregnenolone Alterations Following Pharmacological Agents in Rodents and Clinic Populations

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 69 Neurosteroids Induce Allosteric Effects on the NMDA Receptor Nanomolar Concentrations of Neurosteroids Exert Non-Genomic Effects on the NMDA Receptor Complex

  2008cites this paper
• Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for cognitive performance of mid-aged mice.

  2008cites this paper
• Estrogen, cognition and female ageing.

  2007influential citation
• Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent

  2007cites this paper
• Enhancement of learning and memory performance

  2007cites this paper
• Luteinizing hormone receptor mediates neuronal pregnenolone production via up‐regulation of steroidogenic acute regulatory protein expression

  2007cites this paper
• Effect of tibolone administration on central and peripheral levels of allopregnanolone and β-endorphin in female rats

  2006cites this paper
• Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics

  2006cites this paper
• Oestrus in the Mare with Emphasis on Deviant Behaviour and Adrenal Gland Function

  2006cites this paper
• The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside.

  2006cites this paper
• Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease.

  2006cites this paper
• Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers

  2006cites this paper
• The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease.

  2006cites this paper
• Sex steroids as pleiotropic factors in the nervous system from brain development to brain ageing

  2006cites this paper
• Oestrus in the mare

  2006cites this paper
• The Neurosteroid Allopregnanolone Promotes Proliferation of Rodent and Human Neural Progenitor Cells and Regulates Cell-Cycle Gene and Protein Expression

  2005cites this paper
• Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency

  2004cites this paper
• Disadaptive disorders in women: allopregnanolone, a sensitive steroid

  2004cites this paper
• The Effects of Hormones of the Hypothalamo-Hypophyseal-Adrenal, Renin-Angiotensin, and Thyroid Hormone Systems on the Formation of Dyscirculatory Encephalopathy

  2004cites this paper
• Peptide and steroid hormone receptors as drug targets for enhancement of learning and memory performance

  2004cites this paper
• Impairments in spatial learning and memory: ethanol, allopregnanolone, and the hippocampus.

  2003cites this paper
• [The influence of the hormones of hypothalamo-pituitary-adrenal, renin-angiotensin, and thyroid hormonal systems on formation of vascular encephalopathy].

  2003cites this paper
• Neurosteroid secretion in panic disorder.

  2003cites this paper
• Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women

  2003cites this paper
• Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties.

  2003cites this paper
• Brain neurosteroid changes after paroxetine administration in mice.

  2003cites this paper
• Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal beta-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats.

  2002cites this paper
• Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer's disease.

  2002cites this paper
• Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects.

  2002cites this paper
• Sex differences in androgen receptor immunoreactivity in basal forebrain nuclei of elderly and Alzheimer patients.

  2002cites this paper
• Neurosteroids in depression: a review

  2002cites this paper
• 103 – Aging and Alzheimer's Disease

  2002cites this paper
• Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and beta-endorphin.

  2002cites this paper
• Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women

  2001cites this paper
• Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women.

  2001cites this paper
• Age-related changes of the adrenal secretory pattern: possible role in pathological brain aging.

  2001cites this paper
• Anti-Aging Medicine LiteratureWatch

  2000cites this paper
• Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause

  2000cites this paper
• Anti-Aging Medicine LiteratureWatch

  1998cites this paper
• Neurobiology of Stress

  year unknowncites this paper